TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06437483

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sustained Natural Apophyseal Glides
Description: SNAGs:~Therapist will apply an antero-superior accessory glide to the superior spinous process of the involved motion segment (between C3 to C7) by pushing it towards the direction of eyeball at approximately a 45 degree angle, using the thumb. The other thumb will reinforce the glide. Painless accessory glide will be maintained and subject will slowly turn their head towards the painful or restricted side (that elicited symptoms) and sustain the position for a few seconds. In case of symptom-free, the subject will apply overpressure at the end of restricted range of motion. The glide will be maintained till the head returns to the midline.~Each session will consist of three sets of six to ten repetitions.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sustained Natural Apophyseal Glides
Description: SNAGs:~Therapist will apply an antero-superior accessory glide to the superior spinous process of the involved motion segment (between C3 to C7) by pushing it towards the direction of eyeball at approximately a 45 degree angle, using the thumb. The other thumb will reinforce the glide. Painless accessory glide will be maintained and subject will slowly turn their head towards the painful or restricted side (that elicited symptoms) and sustain the position for a few seconds. In case of symptom-free, the subject will apply overpressure at the end of restricted range of motion. The glide will be maintained till the head returns to the midline.~Each session will consist of three sets of six to ten repetitions.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Kinesiotaping
Description: Kinesiotaping (KT):~Subject will be in comfortable sitting position. Neck of the subject will be thoroughly cleaned with alcohol and sterile gauze pads before the application of Kinesiotape.The layers of KT will be applied in the form of two strips i.e. Y strip and I strip. and applied over the neck in a position of cervical flexion and contralateral rotation and, pasted up and over either ridge of the spine covering the cervical muscles.It extends from T1-T2 to either side of C1-C2.The second layer is I-strip:The overlaying I-strip will be placed perpendicular to the Y-strip, It will be stretched from the both ends, and the middle portion of the tape will be applied first after which tension is released and ends are applied without tension.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Treatment
Description: Hot pack (moist heat) and TENS will be applied, each for 10 minutes.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Treatment
Description: Hot pack (moist heat) and TENS will be applied, each for 10 minutes.
Study: NCT04129073

Intervention type: OTHER
Intervention: Intensive care treatment
Description: Intensive care treatment; Utilization of neuroprognostication tools
Study: NCT05559866

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Apollo ESG
Description: Using only Apollo ESG as approved per label.
Study: NCT05987423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Satralizumab
Description: Satralizumab will be administered by SC injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered by SC injection
Study: NCT06003712

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: Participants will engage in a 10-15 minute mindfulness exercise three times weekly for one month. This mindfulness exercise utilizes guided attention on the breath through an instructional video, aiming to cultivate calmness and alleviate stress.
Study: NCT05080790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dinutuximab Beta, Zoledronic acid, Interleukin-2
Description: Five 5-week cycles (Q5W) of dinutuximab beta, zoledronic acid and low-dose interleukin (IL-2)
Study: NCT06184256

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BfedBwell - Core Curriculum
Description: 12-week core nutrition education curriculum + 12-week tapered maintenance curriculum

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BfedBwell - Core Curriculum
Description: 12-week core nutrition education curriculum + 12-week tapered maintenance curriculum

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BfedBwell - Core Curriculum
Description: 12-week core nutrition education curriculum + 12-week tapered maintenance curriculum

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BfedBwell - Core Curriculum
Description: 12-week core nutrition education curriculum + 12-week tapered maintenance curriculum

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BfedBwell - Core Curriculum
Description: 12-week core nutrition education curriculum + 12-week tapered maintenance curriculum

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BfedBwell - Core Curriculum
Description: 12-week core nutrition education curriculum + 12-week tapered maintenance curriculum

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BfedBwell - Core Curriculum
Description: 12-week core nutrition education curriculum + 12-week tapered maintenance curriculum

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BfedBwell - Core Curriculum
Description: 12-week core nutrition education curriculum + 12-week tapered maintenance curriculum

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BfedBwell - 1:1 Counseling
Description: Individual 1:1 counseling sessions with a registered dietitian

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BfedBwell - 1:1 Counseling
Description: Individual 1:1 counseling sessions with a registered dietitian

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BfedBwell - 1:1 Counseling
Description: Individual 1:1 counseling sessions with a registered dietitian

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BfedBwell - 1:1 Counseling
Description: Individual 1:1 counseling sessions with a registered dietitian
Study: NCT05029336

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Depletion of CD3/CD19 in an autologous stem cell transplant
Description: The purpose of this study is to determine the safety and feasibility of CD3/CD19 depleted autologous stem cell transplant for the treatment of life threatening autoimmune disease. We will perform CD3/CD19 depletion using the CliniMACs device as a means of purging autoreactive T and B cells from the transfused autologous stem cell product, while retaining some immune function, namely natural killer cells and monocytes in the product.
Study: NCT06184256

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BfedBwell - Behavioral Skills
Description: Group-based behavioral skills development sessions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BfedBwell - Behavioral Skills
Description: Group-based behavioral skills development sessions
Study: NCT06241833

Intervention type: DRUG
Intervention: PPI
Description: use of PPI concomitant with DAPT
Study: NCT06211166

Intervention type: DIAGNOSTIC_TEST
Intervention: Digital PCR
Description: digital Polymerase Chain Reaction (dPCR)

Intervention type: DIAGNOSTIC_TEST
Intervention: Digital PCR
Description: digital Polymerase Chain Reaction (dPCR)

Intervention type: DIAGNOSTIC_TEST
Intervention: Digital PCR
Description: digital Polymerase Chain Reaction (dPCR)

Intervention type: DIAGNOSTIC_TEST
Intervention: Quantitative PCR
Description: Real-time Polymerase Chain Reaction (real-time PCR)

Intervention type: DIAGNOSTIC_TEST
Intervention: Quantitative PCR
Description: Real-time Polymerase Chain Reaction (real-time PCR)

Intervention type: DIAGNOSTIC_TEST
Intervention: Quantitative PCR
Description: Real-time Polymerase Chain Reaction (real-time PCR)

Intervention type: DIAGNOSTIC_TEST
Intervention: MFC
Description: Multicolor Flow Cytometry

Intervention type: DIAGNOSTIC_TEST
Intervention: MFC
Description: Multicolor Flow Cytometry
Study: NCT05403281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW6012
Description: Drug: DW6012 Single oral administration of DW6012 after an overnight fast~Drug: Dapagliflozin and Sitagliptin Single oral administration of Dapagliflozin and Sitagliptin after an overnight fast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW6012
Description: Drug: DW6012 Single oral administration of DW6012 after an overnight fast~Drug: Dapagliflozin and Sitagliptin Single oral administration of Dapagliflozin and Sitagliptin after an overnight fast
Study: NCT05960136

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sinus lift in patients with positive COVID-19 history
Description: Sinus augmentation in the posterior atrophic maxilla in patients with positive COVID-19 history

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sinus lift with negative COVID-19 history
Description: Sinus augmentation in the posterior atrophic maxilla in patients with negative COVID-19 history
Study: NCT05591651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment of damaged nipple skin: Preparation with hyaluronic acid
Description: The active preparation will be applied for five days, locally on the damaged nipple skin after every second breastfeeding session, and at least four times in 24 hours, alternating it with breast milk.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment of damaged nipple skin: Neutral preparation without hyaluronic acid
Description: The neutral preparation, containing only white vaseline, will be applied for five days, locally on the damaged nipple skin after every second breastfeeding session, and at least four times in 24 hours, alternating it with breast milk.
Study: NCT06325540

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: indirect pulp capping with theracal pt
Description: indirect pulp capping using the theracal pt material
Study: NCT06184256

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BfedBwell - Behavioral Skills
Description: Group-based behavioral skills development sessions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BfedBwell - Behavioral Skills
Description: Group-based behavioral skills development sessions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BfedBwell - Group Support
Description: Structured group support sessions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BfedBwell - Group Support
Description: Structured group support sessions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BfedBwell - Group Support
Description: Structured group support sessions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BfedBwell - Group Support
Description: Structured group support sessions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Program delivery
Description: Delivery and evaluation of one or more intervention components
Study: NCT05347472

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smartphone application
Description: the smartphone application intervention will consist daily physical therapy exercises program. The application will include all the videos about the exercises and all information about the repetition, frequency, intensity, and position.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham Smartphone application
Description: ham application that includes information and general advice about UI only
Study: NCT05198245

Intervention type: DRUG
Intervention: Rimegepant
Description: Rimegepant 75mg

Intervention type: DRUG
Intervention: Various
Description: Various

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT05729373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEP-363856
Description: once daily tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once daily tablet
Study: NCT05250973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab will be administered subcutaneously.
Study: NCT06325540

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: indirect pulp capping with therabase
Description: indirect pulp capping using the therabase material

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: indirect pulp capping with biodentine
Description: indirect pulp capping using the biodentine material
Study: NCT05250973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered either orally or IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered either orally or IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered either orally or IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib will be administered by SC injection or IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib will be administered by SC injection or IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib will be administered by SC injection or IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered orally or IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered orally or IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered orally or IV.
Study: NCT05537402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab and bevacizumab
Description: Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle and Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: transarterial chemoembolization (TACE) or transarterial radioembolization (TARE
Description: TACE cycles occur every 8 weeks +/- 7 days OR TARE cycles occur every 12 weeks +/- 7 days
Study: NCT06637865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMP761
Description: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMP761
Description: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMP761
Description: intravenous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intravenous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intravenous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intravenous

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: keyhole limpet haemocyanin (KLH)
Description: intramuscular immunization and intradermal challenge

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: keyhole limpet haemocyanin (KLH)
Description: intramuscular immunization and intradermal challenge
Study: NCT06581406

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RP2
Description: Genetically modified herpes simplex type 1 virus for tumor lysis and immune stimulation.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab: human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab: Anti-PD-1 Monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab: Anti-PD-1 Monoclonal antibody
Study: NCT04747431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBFT02
Description: PBFT02
Study: NCT05825989

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Beat Acupunch Regimen
Description: The Healthy Beat Acupunch (HBA) regimen, developed by Chen et al. (2017), is based on the Meridian Theory or Jing-Luo Theory. The HBA regimen focuses on body movement with hands swinging, resulting in the natural swinging of fists that hit on acupoints. There are three phases: phase 1 is activating qi and blood; phase 2 is punching meridians; phase 3 is relaxing body and mind.
Study: NCT05078671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: olaparib treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olaparib
Description: olaparib treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobicistat
Description: Pharmacokinetic booster
Study: NCT04787926

Intervention type: DEVICE
Intervention: Locking Solution
Description: The total duration of the study treatment period will be 90 calendar days, from Visit 1 Pre-Instillation to the last study-related assessment. Two to 3 instillations (1 per lumen per visit) of DuraLock-C 4.0%, 30.0%, or 46.7% (equivalent to the catheter manufacturer's prescribed priming volume) will be instilled 1 to 3 days apart (with a HD schedule of 3 to 4 times per week); each instillation of CLS will remain in the CVC for approximately 24 to 72 hours ± 12 hours, based on their practice preferences. EOS will take place at the patient's next scheduled dialysis session.

Intervention type: DEVICE
Intervention: Locking Solution
Description: The total duration of the study treatment period will be 90 calendar days, from Visit 1 Pre-Instillation to the last study-related assessment. Two to 3 instillations (1 per lumen per visit) of DuraLock-C 4.0%, 30.0%, or 46.7% (equivalent to the catheter manufacturer's prescribed priming volume) will be instilled 1 to 3 days apart (with a HD schedule of 3 to 4 times per week); each instillation of CLS will remain in the CVC for approximately 24 to 72 hours ± 12 hours, based on their practice preferences. EOS will take place at the patient's next scheduled dialysis session.

Intervention type: DEVICE
Intervention: Locking Solution
Description: The total duration of the study treatment period will be 90 calendar days, from Visit 1 Pre-Instillation to the last study-related assessment. Two to 3 instillations (1 per lumen per visit) of DuraLock-C 4.0%, 30.0%, or 46.7% (equivalent to the catheter manufacturer's prescribed priming volume) will be instilled 1 to 3 days apart (with a HD schedule of 3 to 4 times per week); each instillation of CLS will remain in the CVC for approximately 24 to 72 hours ± 12 hours, based on their practice preferences. EOS will take place at the patient's next scheduled dialysis session.
Study: NCT04713553

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2.B.1.351
Description: Intramuscular injection
Study: NCT04975009

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fear conditioning
Description: Participants will learn to associate neutral stimuli with a mildly uncomfortable electrical stimulation to the wrist. The intensity of the electrical stimulus is calibrated prior to the start of the experiment to a level deemed highly annoying but not painful by the participant.
Study: NCT05321693

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Pulsed Current Stimulation
Description: Current has a peak pulse amplitude of 2mA, with a frequency range from 6 to 10 Hz. A battery-powered current stimulator will be used. This device provides stimulation through biphasic and alternating square wave pulse, with random pulse width range from 1 to 20 ms

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Pulsed Current Stimulation
Description: Current has a peak pulse amplitude of 2mA, with a frequency range from 6 to 10 Hz. A battery-powered current stimulator will be used. This device provides stimulation through biphasic and alternating square wave pulse, with random pulse width range from 1 to 20 ms
Study: NCT06309966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BHV-7000
Description: BHV-7000 50 mg. Participants will take blinded investigational product (IP) once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BHV-7000
Description: BHV-7000 75 mg. Participants will take blinded investigational product (IP) once daily
Study: NCT03275805

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Duration of Pavlik Harness treatment
Description: The only intervention that varies from standard of care (12 weeks of treatment) will be the duration of bracing (for the treatment to normalization arm). Patients in both arms will have identical follow up protocols and imaging to closely monitor hip morphology.
Study: NCT06309966

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo taken once daily
Study: NCT06380751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saruparib (AZD5305)
Description: Saruparib (AZD5305) is a potent and selective inhibitor of PARP1, with minimal effect on PARP2.
Study: NCT05878145

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured rehabilitation exercise program
Description: Stretching (10 mins): neck, shoulder, wrist, back; Aerobic exercise (20 mins): cycle ergometer, wheelchair run; Strengthening exercise (15 mins): shoulder press, chest press, front raise, biceps curl, lateral raise, bent over rowing or rowing, bent over lateral raise, triceps extension; Balance training (5 mins); Stretching exercise (10 mins)
Study: NCT05282758

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Free Movement Dance
Description: Free Movement Dance as a physiotherapy intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Modified person-centred progressive resistance exercise
Description: Modified person-centered progressive resistance exercise as a physiotherapy intervention
Study: NCT03275805

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 12 week standard of care
Description: The intervention for this arm will be standard treatment for this pathology.